Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CG-SpikeDown by Caregen for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
CG-SpikeDown is under clinical development by Caregen and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
Data Insights
CG-P5 peptide by Caregen for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
CG-P5 peptide is under clinical development by Caregen and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration....